Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-08
2005-03-08
Andres, Janet (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S007210, C424S009100, C530S350000, C530S387900
Reexamination Certificate
active
06864227
ABSTRACT:
Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.
REFERENCES:
patent: 5624899 (1997-04-01), Bennett et al.
patent: 5635177 (1997-06-01), Bennett et al.
patent: 5864020 (1999-01-01), Bennett et al.
patent: 6303769 (2001-10-01), Cerretti et al.
patent: 6413730 (2002-07-01), Holland et al.
patent: 6479459 (2002-11-01), Cerretti et al.
patent: 6492140 (2002-12-01), Cerretti et al.
patent: 20020146420 (2002-10-01), Bennet et al.
patent: 0 633 315 (1993-03-01), None
patent: 0999 278 (2000-05-01), None
patent: WO 9315201 (1993-08-01), None
patent: WO 9626958 (1996-02-01), None
patent: WO 9626958 (1996-09-01), None
patent: WO 9952541 (1998-04-01), None
patent: WO 9845708 (1998-10-01), None
patent: WO 9908696 (1999-02-01), None
patent: WO 0024413 (2000-05-01), None
patent: WO 0030673 (2000-06-01), None
patent: WO 0030673 (2000-06-01), None
patent: WO 0211785 (2002-02-01), None
patent: WO 0226827 (2002-04-01), None
patent: WO 02058538 (2002-08-01), None
patent: WO 02061055 (2002-08-01), None
patent: WO 02079382 (2002-10-01), None
patent: WO 02102973 (2002-12-01), None
patent: WO 03004057 (2003-01-01), None
Simonet et al., European J. Pharmacology, vol. 216, pp. 135-137, 1992.*
Pasquale, Curr. Opin. Cell. Biol. vol. 9, pp. 608-615, 1997.*
tBruckner et al., Science, vol. 275, pp. 1640-1643, 1997.*
Adams, R.H., et al., “Roles of EphrinB Ligands and EphB Receptors in Cardiovascular Development: Demarcation of Arterial/Venous Domains, Vascular Morphogenesis, and Sprouting Angiogenesis,”Genes Dev. 13:295-306 (1999).
Henkemeyer, M., et al., “Nuk Controls Pathfinding of Commissural Axons in the Mammalian Central Nervous System,”Cell, 86:35-46 (1996).
Orioli, D., et al., “Sek4 and Nuk Receptors Cooperate in Guidance of Commissural Axons and in Palate Formation,”Embo J., 15(22):6035-6049.
Gerety, S.S., et al., “Symmetrical Mutant Phenotypes of Receptor EphB4 and Its Specific Transmembrane Ligandephrin-B2in Cardiovascular Development,”Mol. Cell, 4:403-414 (1999).
Gale, N.W., et al., “Ephrin-B2 Selectively Marks Arterial Vessels and Neovascularization Sites in the Adult, with Expression in Both Endothelial and Smooth-Muscle Cells,”Dev. Biol., 230: 151-160 (2001).
Stein, E. et al., “Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses,”J. Of Cellular and Molecular Biology, 12(5):667-678 (1998).
Stein, E. et al., “Nck Recruitment to Eph Receptor, EphB1/ELK, Couples Ligand Activation to c-Jun Kinase,”The Journal of Biological Chemistry, 273(3):1303-1308 (1998).
Bennett, B. D. et al., “Molecular cloning of a ligand for the EPH-related receptor protein-tyrosine kinase Htk,”Proc. Natl. Acad. Sci. USA, vol. 92, pp. 1866-1870, Mar. 1995.
Bergemann, A. D. et al., “ELF-2, a New Member of the Eph Ligand Family Is Segmentally Expressed in Mouse Embryos in the Region of the Hindbrain and Newly Forming Somites,”Molecular and Cellular Biology, vol. 15, No. 9, pp. 4921-4929, Sep. 1995.
Stein, E. et al., “Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses,”Genes&Development 12:667-678, 1998.
Andres, A. C. et al., “Expression of two noveleph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis,”Oncogene, vol. 9, pp. 1461-1467, 1994.
Folkman, J. et al., “Blood Vessel Formation: What Is Its Molecular Basis?”Cell, vol. 87, pp. 1153-1155, Dec. 27, 1996.
Risau, W., Mechanisms of angiogenesis,Nature, vol. 386, pp. 671-674, Apr. 17, 1997.
Pasquale, E. B., “The Eph family of receptors,”Curr. Opin. Cell. Biol. 9:608-615, 1997.
Wang, H. U. et al., “Eph Family Transmembrane Ligands Can Mediate Repulsive Guidance of Trunk Neural Crest Migration and Motor Axon Outgrowth,”Neuron, vol. 18, pp. 383-396, Mar. 1997.
Asahara, T. et al., “Isolation of Putative Progenitor Endothelial Cells for Angiogenesis,”Science, vol. 275, pp. 964-967, Feb. 14, 1997.
Yancopoulos, G. D. et al., “Vasculogenesis, Angiogenesis, and Growth Factors: Ephrins Enter the Fray at the Border,”Cell, vol. 93, pp. 661-664, May 29, 1998.
Wang, H. U. et al., “Molecular Distinction and Angiogenic Interaction between Embryonic Arteries and Veins Revealed by ephrin-B2 and Its Receptor Eph-B4,”Cell, vol. 93, pp. 741-753, May 29, 1998.
Simonet, S., et al., “Venous and Arterial Endothelial Cells Respond Differently to Thrombin and its Endogenous Receptor Agonist,”European Journal of Pharmacology 216:135-137 (1992).
Yancopoulos, G.D., et al., “Vasculogenesis, Angiogenesis, and Growth Factors: Ephrins Enter the Fray at the Border,”Cell, 93: 661-664 (1998).
Wang, H., “Transmembrane Ephrin Ligands in Neural and Vascular Development,”DAI, 59(11): 5721 (1999).
Anderson David J.
Chen Zhoufeng
Wang Hai U.
Andres Janet
California Institute of Technology
Ropes & Gray LLP
LandOfFree
Artery-and vein-specific proteins and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Artery-and vein-specific proteins and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Artery-and vein-specific proteins and uses therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3437722